

Fish Iridoviridae: infection, vaccination and immune response

Rocío Leiva-Rebollo, Alejandro M. Labella, Juan Gémez-Mata, Dolores Castro, Juan J. Borrego

To cite this version:

Rocío Leiva-Rebollo, Alejandro M. Labella, Juan Gémez-Mata, Dolores Castro, Juan J. Borrego. Fish Iridoviridae: infection, vaccination and immune response. Veterinary Research, 2024, 55 (1), pp.88. $10.1186/s13567-024-01347-1$. hal-04655331

HAL Id: hal-04655331 <https://hal.science/hal-04655331v1>

Submitted on 22 Jul 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

REVIEW Open Access

Fish *Iridoviridae*: infection, vaccination and immune response

Rocío Leiva-Rebollo^{1,2,3†}, Alejandro M. Labella^{1†}, Juan Gémez-Mata¹, Dolores Castro¹ and Juan J. Borrego^{1*}

Abstract

Each year, due to climate change, an increasing number of new pathogens are being discovered and studied, leading to an increase in the number of known diseases afecting various fsh species in diferent regions of the world. Viruses from the family *Iridoviridae*, which consist of the genera *Megalocytivirus*, *Lymphocystivirus*, and *Ranavirus*, cause epizo‑ otic outbreaks in farmed and wild, marine, and freshwater fsh species (including ornamental fsh). Diseases caused by fsh viruses of the family *Iridoviridae* have a signifcant economic impact, especially in the aquaculture sector. Consequently, vaccines have been developed in recent decades, and their administration methods have improved. To date, various types of vaccines are available to control and prevent *Iridoviridae* infections in fsh populations. Notably, two vaccines, specifcally targeting Red Sea bream iridoviral disease and iridoviruses (formalin-killed vaccine and AQUAVAC[®] IridoV, respectively), are commercially available. In addition to exploring these themes, this review examines the immune responses in fsh following viral infections or vaccination procedures. In general, the evasion mechanisms observed in iridovirus infections are characterised by a systemic absence of infammatory responses and a reduction in the expression of genes associated with the adaptive immune response. Finally, this review also explores prophylactic procedure trends in fsh vaccination strategies, focusing on future advances in the feld. **Keywords** Fish *Iridoviridae*, immune response, aquaculture, vaccines, viral infection

Table of Contents

- 1 Introduction
- 2 Type of fsh virus vaccines and their delivery methods
- 3 *Iridoviridae*: taxonomy and host range
	- 3.1 Megalocytiviruses
	- 3.2 Lymphocystiviruses

Handling editor: Stéphane Biacchesi.

† Rocío Leiva-Rebollo and Alejandro M. Labella are frst authors.

*Correspondence:

Juan J. Borrego

¹ Departamento de Microbiología, Universidad de Málaga, Málaga, Spain ² Department of Microbiology, Icahn School of Medicine at Mount Sinai,

New York, NY, USA

³ Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA

3.3 Ranaviruses

- 4 Immune responses of infected and vaccinated fsh to *Iridoviridae*
	- 4.1 *Iridoviridae* infection and immune response in fsh
	- 4.2 Immune response of fsh to *Iridoviridae* vaccination
		- 4.2.1 Megalocytivirus vaccines
		- 4.2.2 Lymphocystivirus vaccines
		- 4.2.3 Ranavirus vaccines
- 5 Conclusions

References

1 Introduction

Among the many viral diseases that threaten the economic stability of the aquaculture sector, iridoviruses are emerging pathogens with a pervasive presence across diverse environmental niches and host species.

© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/.](http://creativecommons.org/licenses/by/4.0/) The Creative Commons Public Domain Dedication waiver ([http://creativeco](http://creativecommons.org/publicdomain/zero/1.0/) [mmons.org/publicdomain/zero/1.0/](http://creativecommons.org/publicdomain/zero/1.0/)) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

jjborrego@uma.es

Signifcant mortality rates characterise these diseases, afecting both wild and farmed animals and establishing viral reservoirs amongst those populations [1]. To mitigate this potentially unsafe impact, it is necessary to implement biosecurity measures that focus on four main areas: fsh, pathogens, environment, and personnel management. These management factors involve selecting pathogen-free broodstock, feeding optimisation, rigorous hygiene and sanitation protocols for facilities, the use of approved, available drugs, methods for microbial pathogens detection, and the disinfection of fertilised eggs, rearing water, and effluents to ensure healthy stocks for fsh farming [2]. Furthermore, it is essential to improve the resilience and health of aquaculture systems against iridovirus infections by integrating prophylactic measures, notably through developing and administering fsh vaccines [3]. Creating efective and state-of-the-art vaccines requires careful consideration of various factors, including identifying suitable vaccine antigens, the vaccine type, and the administration protocols. Crucially, a profound understanding of the fsh immune response is essential for guiding the selection of immune response pathways and the essential determinant genes associated with virus inhibition or elimination. Consequently, studies such as transcriptomic analyses are gaining increasing traction as they offer valuable insights into the intricacies of immune responses across diverse fsh species, thereby facilitating the identifcation of potential therapeutic targets for vaccine development [4].

Numerous studies carried out over recent decades have concluded that fsh vaccination is an efective, easy, and inexpensive method of controlling microbial pathologies and preventing many re-emerging diseases in aquaculture systems. Aquaculture most crucial environmentally friendly disease control strategy is the fsh vaccination procedure. It helps prevent and control viral diseases and signifcantly reduces reliance on antibiotics. Moreover, immunostimulants can enhance the efect of vaccines by boosting the immune mechanisms in fsh and providing specifc long-term protection against one particular microbial infection based on enhancing innate and adaptive immune responses [5].

Building upon these considerations, the main goal of this review is to comprehensively analyse the existing vaccines developed against iridoviral diseases in fsh within the aquaculture sector. It will address the challenges posed by both emerging and re-emerging diseases in aquaculture. Additionally, it aims to consolidate the available information regarding fsh immune responses to iridovirus infections, their subsequent immune responses after vaccination, and the way forward for vaccine development.

2 Type of fsh virus vaccines and their delivery methods

A vaccine is a biologically based preparation designed to enhance immunity against a specifc infectious agent by triggering an innate and/or adaptive immune response to a particular antigen derived from or present in the disease-causing pathogen. Presently, 26 licensed fsh vaccines are commercially available worldwide, catering to various fsh species and ofering protection against a range of fsh pathogens, including certain families of viruses such as rhabdoviruses, birnaviruses, orthomyxoviruses, alphaviruses, alloherpesviruses, and iridoviruses [6]. Vaccines are typically administered through various routes, including oral, injection (intraperitoneal or intramuscular), and immersion [7]. Selecting the most efective route depends on several factors, such as the pathogen, its mode of infection, the immunological memory status, vaccine production methods, labour costs, and the life phase of the fish. The choice of delivery method may impact the immune response and the level of protection against the target pathogen, as the kinetics and magnitude of the innate immune response vary depending on the vaccination route [8, 9].

Oral vaccination incorporates the fsh vaccine into the feed through coating, spraying, or bioencapsulation [10]. Plant and LaPatra reported that this method offers advantages such as cost efficiency (particularly for larger fsh), simplicity, and safe administration across diferent fsh sizes and developmental stages while also inducing minimal stress [11]. Additionally, oral vaccination is a convenient means for boosting immunity during growout periods in cages or ponds. However, it tends to have lower efficacy due to the limited time and level of defence against antigen destruction, degradation, and absorption by the fsh´s gastrointestinal tract. Orally administered vaccines, particularly those containing inactivated whole antigens and a booster vaccine for primary vaccination, elevate the protection against pathogens [12].

Injection methods, specifcally intraperitoneal (IP) or intramuscular (IM) routes, offer advantages over immersion vaccination. They require only a small amount of antigen and provide longer-lasting protection to fsh. IP injection is considered the most efficient and productive way to immunise fsh, often using adjuvants for enhanced protection compared to immersion methods. Recent vaccines have been administered using this route. Conversely, fsh farmers prefer IM delivery for DNA vaccination due to its longer protection duration. However, one drawback of injection methods is a higher incidence of stress-induced fsh mortality following vaccination [9].

Immersion vaccination is efective for immunising fsh against microbial infection, especially with live, attenuated, or vector formulations. This technique can

be carried out through either a dip (a brief immersion for 30 s with a high vaccine concentration) or a bath (several hours with a lower vaccine concentration) [13]. Immersion is widely utilised and recommended for smaller fsh due to its efectiveness, rapidity, convenience, low stress-inducing levels, and its cost-efectiveness. However, one disadvantage is the short duration of fsh immunity, ranging from 3 to 12 months, often necessitating booster doses. Moreover, immersion vaccination is impractical for large fsh due to longer processing times, increased costs, elevated stress levels, and difficulties administering multiple immune stimulants and adjuvants [14].

Inactivated (or 'killed' vaccines) are derived from microbial suspensions treated with physical or chemical agents (e.g., heat, UV, formaldehyde, ethylamine, or β-propiolactone). These agents block microbial nucleic acid replication while preserving antigenicity. Despite being easy to prepare, exhibiting high stability of immunogenicity in feld conditions, and being relatively inexpensive, these vaccines require high inoculation doses and may induce toxic reactions due to immune-enhancing adjuvants. Additionally, the denaturation of proteins can reduce immunogenicity, leading to weaker or shorter-lived immunity [14, 15]. To address this, adjuvants or multiple booster immunisations may be necessary.

Attenuated vaccines consist of live microorganisms lacking the ability to cause a productive infection. They tend to be more immunogenic than inactivated vaccines due to their ability to proliferate, provide cellular and humoral immunity, and ease of host entry. However, they have a short validity period, poor thermal stability, and risk reverting to pathogenic forms and establishing infection in immunocompromised individuals [9]. Various methods, including natural selection, serial passages in cell line cultures, gene deletion, and reverse genetics, are used to obtain avirulent virus strains for attenuated vaccines. Currently, only one commercial vaccine by KoVax is available in Israel based on a live attenuated virus. It targets the carp disease koi herpesvirus (KHV) and is administered through intraperitoneal, oral, or immersion routes [16].

Subunit vaccines utilise only immunogenic components of pathogens, and there is no risk of pathogenicity to hosts or non-target species as they cannot replicate within the host. These components can be isolated directly from the pathogen or produced using recombinant expression vectors such as *Escherichia coli*, yeast, insect cells, and cabbage worms, or designed using in silico analysis. As these vaccines may elicit a weaker immune response, they often require adjuvants or multiple booster immunisations for long-term immunity [17].

DNA vaccines, consisting of plasmid carrying specifc antigenic genes, are safe and advantageous, requiring only immunogenic parts of the pathogen. Moreover, they have other advantages such as the potential to co-administer multivalent vaccines, production fexibility that is scalable and cost competitive, and stability in storage due to an elevation of chemical stability of the plasmid DNA [18, 19]. DNA vaccines do not require adjuvants and can efectively activate both cellular and humoral immunity. DNA vaccines have been developed against various fsh viruses, including rhabdoviruses, herpesviruses, orthomyxoviruses, betanodavirus, togaviruses, birnaviruses, and iridovirus. A recombinant DNA vaccine containing the puK-SPDV-poly2#1 plasmid, encoding several proteins from SAV-3 (CLYNAV), has been approved in Norway and the EU to combat pancreatic disease [20]. Remarkably, research indicates that the method of vaccine administration signifcantly impacts the immune response to DNA vaccines, with oral and immersion routes demonstrating superior fsh immunological protection [21, 22].

Newer RNA-based vaccines offer several advantages over traditional fish vaccines. They have enhanced immunogenicity, easier degradation by normal cellular processes, and improved safety due to the absence of infection or insertional mutagenesis risks [23]. Currently, two major types of RNA-based vaccines exist; these are conventional, non-replicating mRNA and self-amplifying mRNA (i.e., replicons). Self-amplifying RNA vaccines, by replacing genes for virus structural proteins with fsh pathogen antigens, show promise in protecting against various fsh viral diseases [24].

Mucosal vaccines are gaining attention in aquaculture for their longer immunity periods. They may elicit protective responses at mucosal surfaces, inhibiting pathogen replication at the initial site. Live vector vaccines, a subgroup, use genetically modifed non-pathogenic viruses as carriers to express immune-related antigens, including intestinal mucosal immune responses. A signifcant beneft of live vector vaccines is their ability to efectively stimulate cellular, humoral, and mucosal immunisation by inducing antigen expression in vivo [25].

Nanoparticles are increasingly being considered as potential vaccine candidates for use in aquaculture. Their small size allows for distribution throughout the organism via the circulatory system, entering target cells such as capillaries. Nanovaccines offer additional advantages beyond enhanced immune system activation without booster doses. They do not require cold chain maintenance, simplifying storage and distribution logistics and reducing the costs and logistical challenges associated with traditional vaccines [26].

3 *Iridoviridae***: taxonomy and host range**

The family *Iridoviridae* are composed of large doublestranded DNA (dsDNA) viruses with icosahedral symmetry and diameters ranging from 120 to 200 nm. Members of this family have a broad host range and infect vertebrates, including bony fsh, amphibians, and reptiles $[27]$ (Table 1). The genera can be distinguished by the following characteristics: guanine-cytosine (GC) content, nucleotide and protein sequence identity, phylogenetic relatedness, disease manifestations, and antigenicity [27–30].

3.1 Megalocytiviruses

The genus *Megalocytivirus* comprises two species: *Infectious spleen and kidney necrosis virus* (ISKNV) and *Scale drop disease virus* (SDDV). Furthermore, ISKNV species include a large cluster represented by three genotypes, subdivided into clades I and II, generating six clades (Table $1)$ [30, 31]. The second cluster includes strains belonging to the SDDV species. An SDDV-close

Table 1 Taxonomy of the family *Iridoviridae* **and its features**

European chub iridovirus (ECIV) and an unclassifed three-spined stickleback (TSIV) were recently isolated and classified. They have been proposed as species within the MCVs genus [11, 30, 32]. Megalocytiviruses provoke systemic, often life-threatening diseases, characterised by enlarged cells called 'inclusion body-bearing cells' in infected organs and tissues such as the spleen, kidney, gastrointestinal tract, and gills. Inclusion body-bearing cells are hypertrophied cells with large basophilic and granular inclusions that distend the cytoplasm and displace the nucleus. Infected fsh are lethargic and show abnormal body colouring, gill petechiae, and histological changes in the spleen, gills, and gut tract. This can all lead to mortality amongst wild and farmed marine and freshwater fish, including ornamental species [33]. This genus is gaining attention because it causes signifcant mortality that occasionally can reach up to 100% during epizootics in captive fsh populations and experimental infections [29, 32, 34, 35] (Table 1). Additional fle 1 lists the main species of fsh, both marine and freshwater,

which have been described as susceptible to infection with megalocytiviruses. Megalocytiviruses are listed by the World Organization for Animal Health (WOAH, formerly the OIE) in chapter 1.3 as the causative agent of red sea bream iridovirus diseases [28, 36–38].

3.2 Lymphocystiviruses

The genus *Lymphocystivirus* contains four species: *Lymphocystis disease virus 1* (LCDV1), *Lymphocystis disease virus 2* (LCDV2, LCDV-C), *Lymphocystis disease virus 3* (LCDV3, LCDV-Sa) and *Lymphocystis disease virus 4* (LCDV-4) (Table 1). LCDV infects more than 100 species of marine and freshwater fsh (Additional fle 1) [30–41], resulting in wart-like lesions, usually on the external surface of infected fish. These lesions consist of clusters of individual infected cells (about 1 mm in size), mainly on the skin but sometimes in internal organs. Viral morbidity can be high, and, in some cases, large numbers of these lesions can impair the mobility and feeding of infected fsh, indirectly contributing to mortality [42, 43]. The duration of virus proliferation in fish is temperaturedependent and highly variable, ranging from fve days to nine months.

3.3 Ranaviruses

The genus *Ranavirus* comprises versatile pathogens capable of causing systemic infections in lower vertebrates (classes Reptilia, Amphibia, and Osteichthyes). The broad host range of this genus is a major reason why the WOAH lists ranaviruses as notifable amphibian and fsh pathogens. The *Ranavirus* species can be distinguished by several criteria, including nucleotide sequence identity, phylogeny, host range, and protein and genomic characteristics [29]. According to the International Committee on Taxonomy of Viruses (ICTV) report, this genus comprises seven species (Table 1). It has been hypothesized that ranaviruses have jumped from fsh to amphibians and reptiles, the latter probably because they often share habitat with susceptible fsh and amphibian species [44]. Brenes et al. demonstrated that ranaviruses can be transmitted through water in cold-blooded vertebrates by cannibalism, parenteral injection, direct contact, or environmental exposure [45]. Outbreaks in some species, such as European perch (*Perca fuviatilis*) can be more lethal than in other species depending on the species, virus and age and health status of the host (Table 1). *Ranavirus* infections cause high levels of morbidity and mortality in their susceptible farmed and wild host species because the mode of transmission promotes a rapid spread of the virus $[46]$. Typical symptoms of infection in fsh include loss of buoyancy, erratic swimming, anorexia, red swollen gills, haemorrhages (internal organs, skin, and eyes), and focal and/or generalized necrosis of

the hematopoietic tissues (the spleen, renal hematopoietic tissue, and the liver) and other cells and organs (the gill and gastrointestinal epithelial cells, and the pancreas) [47].

Additional file 1 shows the main host fish species of ranaviruses [29, 48–51].

Table 1 shows the optimal replication in vivo and in vitro and the percentage of mortality associated with these genera.

4 Immune responses of infected and vaccinated fsh to *Iridoviridae*

4.1 *Iridoviridae* **infection and immune response in fsh**

In line with numerous pathogens, iridoviruses overcome macrophage and host antiviral barriers by down-regulating reactive oxygen species, turning these immune cells into vehicles for virus spread and persistence [52]. Furthermore, another characteristic of various members within the family *Iridoviridae* is the inefectiveness of several fsh IFN/Mx antiviral proteins in preventing infection. For example, the Mx of Japanese founder (*Paralichthys olivaceus*) can inhibit the replication of two rhabdoviruses (HIRRV and VHSV) but is unable to inhibit the replication of Red Sea bream iridoviral virus (RSIV) [53]. Similarly, Mx proteins from barramundi (*Lates calcarifer*), Senegalese sole (*Solea senegalensis*), and rainbow trout (*Oncorhynchus mykiss*) show no antiviral activity against the megalocytivirus TGIV and the ranaviruses ECV and EHNV, respectively [54–56]. Interestingly, gilthead seabream possesses at least three Mx isoforms that efectively inhibit the replication of the rhabdovirus VHSV and the lymphocystivirus LCDV-Sa (isoform Mx1), both iridoviruses ECV and LCDV-Sa (isoform Mx2) and the rhabdovirus VHSV (isoform Mx3) [57, 58]. This is the first example of a teleost Mx molecule effectively inhibiting DNA virus infection. Therefore, the efficacy of the teleost IFN/Mx response may determine the specific susceptibility of each fish species to viruses. In this manner, after infection with the megalocytivirus TGIV (genotype II, clade 2), high levels of phagocytic basophilic and eosinophilic mononuclear leukocytes have been found to contain TGIV genomic DNA in their nuclei. Certainly, TGIV has evolved complex and regulated strategies to overcome and exploit the host immune cells, constituting a viral immune evasion and dissemination mechanism that is a hallmark of all vertebrate iridoviruses. Iridoviruses also encode genes that interfere with the host immune response. Sequence analysis has identifed several putative genes that may help to suppress host immunity. These putative immune evasion proteins include the viral homolog of eIF-2a (vIF-2a), a viral homolog of RNAse III, a virusencoded CARD (caspase activation and recruitment

domain)-containing protein, a viral homolog of steroid dehydrogenase (β-HSD), encode viral proteins (VP48, VP122, VP312) that regulate by inhibiting autophagy, a putative Bcl-2-like protein, and one or more tumour necrosis factor (TNF) receptor homologs [59–61].

Holopainen et al. found that infecting the *Epithelioma papulosum cyprini* (EPC) cell line with the ranaviruses FV3, ECV, DFV, and EHNV, led to diferent infammatory gene expression profles [62]. Specifcally, infection with EHNV and FV3 induced the expression of the proinfammatory genes *tnfα* and *il1ß*, whereas ECV and DFV induced the transient up-regulation of the immunosuppressive gene transforming growth factor-beta (*tgfß*). Additionally, all ranaviruses induced the expression of apoptotic components and ß2-microglobulin genes, which are critical for surface MHC class I expression and, therefore, for cytotoxic T-cell function. This suggests that the adaptive immune response may also be triggered by these viral infections.

MicroRNAs (miRNAs) are a type of non-coding RNA that play a crucial role in various cellular functions [63]. However, their role in viral infection mechanisms and cellular immune response in fsh remains poorly understood [64]. Li et al*.* investigated the role of miR-124 in SGIV-infected, orange-spotted grouper (*Epinephelus coioides*) and the subsequent host immune responses [65]. The expression level of grouper miR-124 was significantly up-regulated after SGIV infection; and although miR-124 does not afect the virus entry, the up-regulated miR-124 could afect the SGIV-induced cytopathic efects (CPEs) and viral gene expressions. Overall, grouper miR-124 could promote viral replication and down-regulate fsh immune response by targeting JNK3 (Jun N-terminal kinase) and p38a mitogen-activated protein kinase (MAPK). Similarly, Wu et al. identifed numerous megalocytivirus-induced, non-coding RNAs and their interactive targets, highlighting the profound involvement of non-coding RNAs in megalocytivirus infection and host immune responses $[66]$. It is worth noting that infection suppresses the expression of mir-144, a factor crucial in activating RLR and IRF7 expression, thereby facilitating viral clearance. Additionally, mir-144 indirectly regulates the JACK-STAT pathway and IFNγ, contributing to the immune evasion mechanism. Another signifcant observation is the activation of mir-409, which inhibits the expression of STAT1, thereby suppressing the infammatory response and promoting viral infection.

Several microarray studies have investigated the transcriptional response of fish to iridovirus infection. Thus, Huang et al. investigated diferentially expressed genes (DEGs) in the spleen of the orange-spotted grouper) infected with the ranavirus SGIV [67]. Further KEGG (Kyoto Encyclopedia Genes and Genomes) analysis revealed that the cellular metabolism, and intracellular immune signaling pathways, were present in the infected libraries. Certain genes associated with the MAPK, chemokine, toll-like receptor, and RIG-I (retinoic acidinducible gene I) signaling pathways were altered in response to SGIV infection.

Park et al. studied the DEGs in the spleen of rock bream (*Oplegnathus fasciatus*) infected with the megalocytivirus RBIV (genotype II, clade 2) [68]. Sequencing of the whole transcriptome in infected fsh showed that the DEGs were immune-related genes such as interferoninduced and Fc receptor-like. Interleukin-10, perforin-1, and inhibitor of nuclear factor $κ$ -β kinase, complement system (except C4) genes were up-regulated; but IL1β, λ-chain of immunoglobulin (Ig), α-chain Ig, and complement factor H were down-regulated.

Carballo et al. experimentally infected Senegalese sole with the lymphocystivirus LCDV-Sa and studied a set of DEGs in the kidney and intestine for 15 days $[69]$. They found that LCDV-Sa infection activated immune-related genes, such as interferons, cytokines and their receptors, chemokines, prostaglandins, lysozyme, hepcidin, complement fractions, and several clusters of diferentiation of the antigens (*cd4*, *cd8a*, and *cd8b*). These results are a systemic host defence response to viral infection. Previously, Hu et al. also found that several IFN-related genes (*irf3*, *irf5*, *irf7*, *irf8,* and *irf9*) were induced in several organs of Japanese founder after poly(I:C) or LCDV-C challenge [70].

Liu et al. compared the immune responses of groupers to infection with the megalocytivirus TGIV and the ranavirus GIV [71]. A total of 17 common and fve specifc pathways were found to be signifcantly diferentially expressed after infection with both iridoviruses. TGIV infection activated the spliceosomal pathway, whereas the glycolysis/gluconeogenesis pathway was associated with TGIV infection, which may explain the diferent pathologies and symptoms induced by these viruses.

Leiva-Rebollo et al. analysed the immune gene expression response in gilthead seabream (*Sparus aurata*) that were infected with the lymphocystivirus LCDV-Sa [72]. They found viral DNA and transcripts in all the inoculated fsh, demonstrating that the virus is capable of causing systemic and asymptomatic infections. The expression of 23 immune-related genes was analysed in the head kidney and intestine. Of these, fve IFN-Irelated genes (*ifn*, *irf3*, *mx2*, *mx3*, and *isg15*), and two of the interleukin genes (*il10* and *ck10*) were up-regulated, while genes related to the infammatory process (*tnfα, il1ß*, *il6*, *casp1*) were neither diferentially expressed nor down-regulated in the head kidney. The expression profle in the intestine difered in relation to type I INFrelated genes. An up-regulated gene for complement *C3* and immunoglobulin heavy constant mu (*ighm*) expression was detected in both organs. Finally, the transcription of *nccrp1* and *mhcIIα* was induced in the head kidney, whereas *tcrb* expression was down-regulated in both organs. In short, LCDV-Sa triggers an immune response in this particular fish species. This response is characterised by an activation of the type I IFN system and a lack of systemic inflammatory response. This may be connected to the virus's observed persistence in that fish species.

In another study, Carballo et al. infected Senegalese sole post-larvae with the lymphocystivirus LCDV-Sa using two routes: artemia as a vehicle of feed and immersion [73]. An expression analysis of 22 genes related to the innate immune defence system showed apparent differences depending on both the route of infection and the time course of the response. Most antiviral defence genes (proinfammatory cytokines, complement, lysozyme, and T-cell markers) were rapidly induced in the feed-infected post-larvae. The most defensive genes were induced later in the post-larvae that were infected through immersion, in contrast. These results confirmed horizontal waterborne and feed transmission of LCDV-Sa, although with diferent patterns of histopathological damages, virus distribution, and route-specifc expression gene profles.

The transcriptional responses of orange-spotted grouper to the ranavirus SGIV infection were studied by Yang et al. [74]. KEGG analysis showed that two immune-related pathways were overexpressed: the p53 (related to cell cycle, cellular senescence, and apoptosis) and the peroxisome proliferator-activated receptor (PPAR). The latter is a regulator of innate and adaptive immunity that stimulates an anti-infammatory activity in several cell types by inhibiting the expression of *AP-1* and *NF-*κ*B* infammatory genes. Furthermore, a comparable phenomenon was observed in grouper infected with SGIV, where the up-regulation of Krϋppel-like factor 9 (KLF9) and proprotein convertase subtilisin/kexin type 9 (PCSK9) was noted. This up-regulation inhibited the expression of numerous interferon-related cytokines and infammatory cytokines, thereby facilitating the expression of SGIV-related genes (*mcp*, *litat*, *icp-18*, and $vp19$) [75, 76]. Therefore, susceptibility or resistance to fsh diseases caused by iridoviruses may be linked to various pathways, gene expressions, and genetic markers.

The study by Kim et al. investigated the transcriptomic changes induced by the megalocytivirus RBIV infection in the spleen rock bream fish $[77]$. The DEGs associated with viral infection included unigenes of the cell cycle, DNA replication, transcription, translation, glycolysis activity, and endogenous apoptosis. Several unigenes exhibited a signifcant decrease in expression, such as the lymphocyte-mediated immune system, antigen presentation, and platelet activation. These results enhance RBIV infection and compromise host defence. The authors also found an overexpressed gene in the infective course, the gene *hub* (a pre-mRNA processing factor 19), which could be a potential candidate

for fsh vaccination studies against these viruses.

Recently, Domingos et al. investigated the expression of immune genes in barramundi following infection with the megalocytivirus SDDV $[78]$. The predominantly activated genes found were those related to innate immunity, such as pattern recognition (lectin, chemokine, and interleukin receptors), infammatory cytokines, TNF, chemokines, complement factors, and immune signal transduction adaptor CD molecules. In contrast, gene families associated with the adaptive immune response (B- and T-cell receptors and MHC) were signifcantly down-regulated in infected barramundi. According to these results, megalocytivirus infection induces the activation of genes related to innate immunity but down-regulates genes associated with adaptive immunity.

Zheng et al. studied the giant grouper's (*Epinephelus lanceolatus*) antiviral immune response to the spotted knifejaw iridovirus SKIV (genotype II, clade 2) [79]. KEGG analysis showed that several innate immune and signalling pathways were signifcantly activated in response to SKIV infection, potentially synergistically contributing to viral clearance. Furthermore, the authors suggest that IRF3 and IRF7 may be involved in the host fsh ability to resist viral infection. A recent study conducted by Niu et al*.* in mandarin fsh infected by ISKNV revealed that the expression of TRIM59 plays a pivotal role in determining the function of IRF3 and IRF7, exhibiting antiviral activity. Generally, TRIM59 negatively regulates ISKN infection and the expression of IRF3/ IRF7-mediated signal genes [80]. In addition, a correlation between the methylated status of the genome of ISKNV and its ability to evade the immune system has recently been discovered, suggesting that an increase in methylation levels allows the virus to sidestep host immune responses [81].

Guo et al*.* performed a transcriptomic analysis to determine the molecular mechanisms induced by ranavirus SGIV infection in grouper spleen cells [82]. SGIV infection activated more than 100 DEGs, the most important of which were the cytoskeleton signalling pathway (involved in the cell rounding during CPE in infected cells) and the MAPK signalling pathway (related to SGIV-induced cell death). In addition, during viral infection, a MAPK gene involved in virus assembly and replication (*c-Jun*) was expressed. On the contrary, most DEGs involved in the immune response (IFNs and infammatory signalling) were down-regulated during SGIV infection, which may indicate the virus's potential immune evasion mechanism.

4.2 Immune response of fsh to *Iridoviridae* **vaccination**

Table 2 details the diferent types of vaccines developed to prevent or reduce infections caused by viruses in the subfamily *Alphairidovirinae*. There are currently only a few commercially available vaccines, such as the formalin-killed vaccine for RSIVD in Japan and AQUAVAC® IridoV in Singapore. The AQUAVAC[®] IridoV vaccine has been shown to provide immunity against iridoviruses [83, 84].

4.2.1 Megalocytivirus vaccines

Nakajima et al. found that a formalin-inactivated vaccine against RSIV (genotype II, clade 2) infection reduced mortality in red sea bream. This protective effect was due to the enhanced fsh-specifc immune response [85, 86]. In a subsequent study, Caipang et al. observed that using the same vaccine, virus, and fsh host resulted in an increase in serum levels of neutralising antibodies and enhanced expression of MHC class I. This occurred when fish were vaccinated with either the intact formalin-inactivated vaccine or its protein derivatives [87]. However, only those fsh vaccinated with the intact vaccine survived the viral challenge. This suggests that the fsh's survival was due to cell-mediated immunity, not serum-neutralizing antibodies. Subsequently, Kwon et al. prepared a formalin-inactivated RSIV (genotype II, clade 2) vaccine, and rock bream specimens were injected with diferent doses of the megalocytivirus vaccine formulations, with or without squalene or aluminum hydroxide as an adjuvant $[88]$. The results showed no differences in neutralising antibody titers. Vaccine efficacy and fsh survival rates were dependent on vaccine dose and temperature.

Shimmoto et al*.* investigated the immunogenicity of subunit vaccines against RSIV (genotype II, clade 2) infection using three viral capsid proteins (18R, 351R, and MCP) [89]. Juveniles of red sea bream (*Pagrus major*) were intraperitoneally (IP) vaccinated with the recombinant formalin-killed *Escherichia coli* cells expressing these capsid proteins. They then underwent challenge infection with RSIV. Higher survival rates were observed in fsh that received the 351R vaccine compared to the unvaccinated control group. A viral protein (351-R) was co-expressed with the bacterial glyceraldehyde 3-phosphate dehydrogenase as a fusion protein and showed improved protection against RSIV infection, leading to higher survival rates and increased levels of neutralising antibody levels.

Park et al. constructed a DNA vaccine by cloning the ORF 055L of RSIV into a plasmid containing a cytomegalovirus promoter. $[90]$. They investigated the ability of the pcDNA-055 DNA vaccine to induce neutralising antibodies against RSIV, determining the antibody efficacy using virus-inoculated BF-2 cell cultures. In another study, a DNA vaccine containing a plasmid encoding the MCP and an ORF of RSIV was developed and tested in red seabream by Caipang et al*.* [91]. MHC class I transcript expression increased in vaccinated fsh. This pattern of expression was similar to that previously obtained by the same authors using a formalin-inactivated RSIV vaccine [87].

Fan et al. developed a formalin-inactivated vaccine against TRBIV (genotype III, clade 1) in turbots [92]. IM administration of the vaccine produced a high number of neutralising antibodies in the fish. The authors found that both subcutaneous and bath administration of the vaccine caused a drastic reduction in fsh mortality. Zheng et al. developed a DNA vaccine against TRBIV [93]. Individual turbots were inoculated with a recombinant plasmid based on a eukaryotic plasmid (pVAX1) carrying a fragment of the *mcp* gene containing two antigenic epitopes of TRBIV. The vaccine induced both specifc and non-specifc cellular and humoral immune responses. In vaccinated fsh, the activated up-regulating TFN, Mx, CXCR, and IFN expressions trigger an antiviral immune response in the host. In addition, after a TRBIV challenge, the vaccinated fsh showed a higher survival rate, producing specifc serum antibodies.

Dong et al. developed a formalin-killed cell-cultured vaccine against ISKNV (genotype I, clade 1) that protected more than 90% of vaccinated mandarin fsh (*Synchiropus splendidus*) [94]. IgM-mediated immunity was the main response in vaccinated fsh. In addition, six proteins were characterised as potent immunogens of ISKNV that specifcally reacted with the sera antibodies. Zeng et al. reported the results of a gene-deleted live attenuated vaccine (ΔORF022L) in mandarin fsh against ISKNV [95]. Vaccine protection showed a dose-dependent response, with 100% survival achieved at higher doses in vaccinated fsh challenged with ISKNV. In addition, the vaccine induced anti-ISKNV-specifc neutralising antibody responses, mainly IgM.

For ISKNV, Fu et al*.* cloned the MCP gene of this megalocytivirus into a prokaryotic expression vector pBV220 [96]. Juvenile mandarin fish were vaccinated via IP with recombinant MCP and an adjuvant, leading to high levels of specifc antibodies and lymphocyte proliferation in vaccinated fsh. However, the immune response was found to be dose-dependent. In another study by the same authors, the *mcp* gene of ISKNV was cloned into a eukaryotic expression vector pcDNA3.1+(pcMCP) [97]. The immune response was induced by the IM injection of Chinese perch (*Siniperca chuatsi*) with pcMCP

supplemented with the QCDC adjuvant. The expression levels of type I IFN system genes, including IRF-7, IRAK1, Mx, and Viperin, were up-regulated at 6 h, while a second peak in the expression levels of IRF-7 and Mx gene was obtained at 21 days post-vaccination. In addition, a remarkable increase in IgM levels was noted. The relative percentage survival (RPS) of Chinese perch vaccinated with pcMCP supplemented with adjuvant was 80% at 28 days post-vaccination. Later, Li et al*.* cloned the ORF093 gene of ISKNV, a predicted transmembrane protein, into a eukaryotic expression vector [pcDNA3.1. $(+)$] [98]. The efficacy of the vaccine was high compared to unvaccinated Chinese perch, with an RPS of \sim 51%.

Fu et al. [99] cloned the ORF086 gene, encoding an early protein helicase of ISKNV, into the prokaryotic pET32a (+) and the eukaryotic pcDNA3.1 (+) expression vectors. The mortality rate of vaccinated mandarins was reduced, with a survival rate of more than 63%. Transcriptional analysis of non-specifc and specifc immunerelated genes revealed that IRF-7, IRAK1, Mx, Viperin, and IgM expression levels were strongly up-regulated in the vaccinated groups after immunisation. Throngnumchai et al. developed an ISKNV subunit vaccine by cloning the MCP gene of ISKNV into *E. coli* [100]. Nile tilapia specimens immunised with recombinant MCP showed signifcantly higher serum antibody titres than the control. In addition, the main immune-related genes activated in the spleen and the kidney in immunised fsh corresponded to *mhcI*, *mhcII*, *il1β*, and *il4*.

Single-walled carbon nanotubes (SWCNTs) were used as a candidate for the ISKNV-DNA vaccine carrier to develop an immersion vaccine for juvenile mandarin fsh $[101]$. The immune response obtained (immune-related gene expression, serum antibody production, enzyme activities, and C3 levels) was signifcantly enhanced in fsh that had been vaccinated with SWCNTs-pcDNA-MCP compared to those vaccinated without the carrier. After 14 days of vaccination, the RPS reached 82.4% with SWCNTs-pcDNA-MCP, while only 54.2% was achieved in fsh vaccinated with naked pcDNA-MCP. Zhao et al. developed another study based on the SWCNT-based subunit vaccine system (SWCNT-MCP) encoding the MCP gene of ISKNV [102]. A stronger and longerlasting immune response (serum antibody production, enzyme activities, and immune-related gene expression) was induced in juvenile mandarin fsh vaccinated by immersion compared to those vaccinated with MCP alone. Moreover, additional research has underscored the immune-potentiating impact of SWCNT employed in subunit vaccines against TGIV. This enhancement is demonstrated by increased survival rates due to higher antibody levels, improved activity of specifc enzymes such as superoxide dismutase, alkaline phosphatase, and acid phosphatase, and the up-regulation of the immunerelated gene expression [103].

Zhu et al. [104] used baculovirus technology to develop a live vector vaccine, BacMCP, containing the MCP coding sequence of ISKNV and driven by a CMV promoter. Immune-related genes (*IgM*, *tgfβ*, *il1β*, *il8*, *tnfα*) were overexpressed in BacMCP-vaccinated groups of largemouth bass (Micropterus salmoides). Vaccine efficacy depended on the route of inoculation and fish size, being 100% in small largemouth bass.

Shin et al. expressed a recombinant major capsid protein (rMCP) of RBIV in transgenic rice callus [105]. The rock bream specimens were immunised by feeding the rMCP in lyophilised rice callus powder. This vaccine induced intestinal mucosal immunity, as evidenced by higher serum IgM titers against rMCP in vaccinated fsh and also by an increased survival rate after the iridovirus infection. Jung et al. evaluated the efficacy of squalene, aluminium hydroxide, and saponin as adjuvants of an inactivated vaccine to protect rock bream against RBIV infection [106]. Saponin induced an antiviral immune response (*il1ß*, *mx*, and *pkr* gene transcripts) and increased the survival rate of vaccinated fsh after RBIV infection without producing side efects and with immunological memory. In addition, Ahn et al. engineered a plant-based vaccine expressing a recombinant MCP from RSIV combined with surface display on *Lactococcus lactis (L. lactis)*. The plant-produced MCP, when displayed on *L. lactis*, was evaluated in mice models to assess its immunogenicity. The study demonstrated a strong immune response indicated by dose-dependent ELISA signal intensities [107].

In another study, Jung et al. [108] investigated the potential efficacy of a viral membrane protein (ORF008L) to protect rock bream from RBIV infection. Fish vaccinated with ORF008L-based DNA showed signifcant protection at four and eight weeks post-vaccination, signifcantly inducing the gene expression of *tlr3*, *MyD88*, *mx*, *isg15*, *pkr*, *mhcI*, *Fas*, *Fas* ligand, *caspase* 9 and 3. The same authors evaluated the ankyrin (ANK) repeat-containing proteins to induce protective immunity in RBIVinfected rock bream [109]. Fish were vaccinated with an ANK-based DNA vaccine and infected with RBIV by IP four to eight weeks after vaccination. At 7 days post-vaccination, the DNA vaccine induced an immune response characterised by the activation of genes related to TLR, IFN, and apoptosis pathways (*tlr3*, *tlr9*, *MyD88*, *mx*, *isg15*, *pkr*, *mhcI*, *perforin*, *Fas*, *Fas ligand*, and *caspase 8*, *9*, and *3*). The levels of inflammatory cytokines gene expression (*il1ß*, *il*8, and *tnf*α) did not increase in the vaccinated fsh. High protection was initially achieved in the vaccinated group at four weeks post-vaccination, but it decreased over time. The authors found that 100% of the

vaccinated fsh survived reinfection with a higher concentration of RBIV.

Mahardika and Mastuti produced a crude subunit vaccine using the MCP of GSDIV (genotype II, clade 2), which was inserted into an expression system vector and cloned into *E. coli* [110]. *E. coli* that expressed the MCP protein was inactivated with formalin, and this crude subunit vaccine was IM injected into humpback grouper (*Cromileptes altivelis*) specimens. The vaccination improved virus protection and reduced fsh mortality.

Guo et al. investigated the protective efect of a bivalent inactivated vaccine developed against Oxyeleotris marmoratus iridovirus (OMIV, genotype II) [111]. A transcriptomic profling study was conducted using RNA sequencing of spleen tissues at various time points after vaccination and OMIV infection. After immunisation, the immune response led to increased production of proinfammatory cytokines (such as IL12). Furthermore, it triggered both cell-mediated and humoral immune responses by activating CD8+cells, TCR, MHC I, MHC II, IgM, and $CD4 +$ cells. The authors noted a significant increase in survival rate, reaching 100% after a lethal dose. This led to a secondary immune response characterised by the activation of cellular and humoral immunity seven days after the OMIV challenge.

4.2.2 Lymphocystivirus vaccines

Zheng et al. investigated the expression of a DNA vaccine (pEGFP-N2-LCDV 0.6 kb) against LCDV in Japanese flounder $[112]$. This vaccine prevented the development of tumour growth in vaccinated fsh. Later, Tian et al*.* formulated a DNA vaccine against LCDV contained in PLGA microcapsules to prevent DNA denaturation by nucleases in the gastrointestinal tract of Japanese founder $[113]$. The microencapsulated vaccine significantly increased the serum of specifc antibodies against LCDV for up to 24 weeks. The same authors prepared nanoparticles of PLGA to encapsulate the developed vaccine against LCDV for the oral immunisation of Japanese flounders $[114]$. The nanoparticle vaccine stimulated the immune response of the fsh by increasing antibody, superoxide dismutase, and lysozyme levels, and also by activating phagocytosis.

Zheng et al. [115] developed a DNA vaccine carrying the LCDV *mcp* gene (pEGFP-N2-LCDV 0.6 kb) against LCDV-C. Vaccinating Japanese flounder via IM injection activated genes involved in the infammatory process and triggered specifc cellular and humoral immune responses. Later, the same authors tested this DNA vaccine in Japanese founder specimens using two routes: IM and subcutaneous injection $[116]$. The results obtained suggest that the humoral and cell-mediated immune responses depend on the route of vaccination used.

A new DNA vaccine against LCDV-Sa was developed by Leiva-Rebollo et al. The vaccine was constructed by cloning the *mcp* gene into a plasmid and applied to gilthead seabream specimens via the IM route $[117]$. This vaccine induces an immune response characterised by the overexpression of genes involved in the infammatory process and induces a humoral immune response characterised by the production of specifc neutralising antibodies. In another study, the same authors [118] showed that the DNA vaccine induced an immune response in gilthead seabream, characterised by an increase in deregulated genes in the hematopoietic organs of vaccinated fsh. Using the OpenArray® platform, fsh vaccination signifcantly reduced virus replication in the vaccinated fsh and resulted in the expression of immune genes related to virus recognition (*tlr9*), humoral and cellular response (*rag1* and *cd48*), infammation (*csf1r, elam, il1β*, and *il6*), antiviral response (*isg15, mx1, mx2, mx3*), cellmediated cytotoxicity (*nccrp1*), and apoptosis (*prf1*). The exclusive modulation of the immune response induced by the vaccination seems to control the progression of the infection in the experimentally challenged gilthead seabream.

4.2.3 Ranavirus vaccines

Ranavirus vaccines have so far been scarcely developed and studied. Orange-spotted groupers vaccinated with two inactivated ranavirus SGIV formulations showed high effectiveness, with over 90% survival rates among immunised fsh [119]. Both vaccines induced a nonspecifc antiviral immune response characterised by the expression of pro-infammatory cytokines and IFN-I-stimulated genes (*mx1* and *isg15*). One month after vaccination, the vaccine induces specifc humoral and cellular immune responses through the activation of MHC class I and cytokine (*il8*) genes and by the production of specifc serum antibodies. Ma et al. developed a water-in-oil formulation of a formalin-killed bivalent vaccine (GrouperVAC-Irido-R-Vh) against the ranavirus GIV $[120]$. The vaccine, inoculated by IP injection into juvenile groupers, showed a protective role against the ranavirus infection. Yu et al. [121] developed an SGIV ORF19R (SGIV-19R) encoding viral membrane protein constructed in pcDNA3.1-HA and used it to evaluate the immunoprotective efects in groupers. Transcript levels of *tnfα*, *il1β*, *mx1*, and *IgM* genes were signifcantly upregulated in the spleen, liver, and kidney of vaccinated groupers. However, SGIV challenge experiments showed that the relative percentage of survival induced by the vaccine ranged from 49.9% to 75%. Another study was conducted to develop an efective vaccine against SGIV using spores of *Bacillus subtilis* WB600 as a vehicle for the VP19 protein displayed on the surface administrated

orally to groupers. This vaccine generated not activated innate immunity but also induced cellular immunity and antiviral activity, thus increasing the survival rate [122].

Yi et al. [123] constructed a DNA vaccine by inserting the cloned largemouth bass virus (LMBV)-*mcp* gene into the $pCDNA3.1(+)$ -flag plasmid. The DNA vaccinated group of the largemouth bass group showed signifcantly up-regulated expression of *il1β*, *il8*, *tnfα,* and *mx* genes in the spleen, head kidney, and liver. All fish immunised with the DNA vaccine produced a high titre of LMBVspecifc neutralising antibodies during the immunisation period.

5 Conclusions

The research outlined in this review demonstrates unequivocally that immunity against iridoviruses is multifaceted and intricate in nature and is probably infuenced by species and developmental stage specifcity. Furthermore, these investigations reveal signifcant gaps in our comprehension of the immune responses these pathogens elicit, as well as potential defciencies in the host capacity to generate robust defenses capable of controlling and eradicating such infections. The family *Iridoviridae's* numerous, highly efective mechanisms for evading host immune components are of particular concern. This promotes viral persistence, facilitates dissemination, and broadens the host range. Based on the existing data on the immune response triggered by iridovirus infection, most infections lead to a systematic decrease in infammatory responses and suppression of the adaptive immune system. Considering these observations, it seems that the virus may be using certain mechanisms to avoid detection by the host immune system. Understanding these immune evasion pathways may aid in developing new vaccination strategies against various viruses from the *Iridoviridae* family.

Currently, the availability of fsh virus vaccines is very limited, and the licensed vaccines cannot fully meet the needs of the aquaculture industry. Therefore, more efforts are required to meet aquaculture needs by intensifying research into the development of highly efective aquatic vaccines.

In the case of iridovirus vaccines, future research will focus on understanding the mechanism of mucosal immunity and its relationship with systemic immunity. In addition, further studies are needed on antigen processing for vaccine production, efective doses, vaccinecoating materials and carriers, and adjuvants. Other important aspects to be considered include the duration of immunisation, the number of boosters, and the physiology and developmental stages of the fsh. It is also necessary to improve the evaluation system of fish vaccines

The selection of appropriate viral antigens is critical for the optimal vaccine design. The rapid development of omics such as genome, functional genome, proteome, and metabolome, along with genome editing technologies, may offer crucial insights into the genomes of fish iridoviruses, their infection process, and the identifcation of genetic targets for highly efective vaccines. It is clear that nucleic acid-based vaccines, such as DNA vaccines, live vector vaccines, and mRNA vaccines will play a signifcant role in preventing viral infectious diseases in aquaculture.

Supplementary Information

The online version contains supplementary material available at [https://doi.](https://doi.org/10.1186/s13567-024-01347-1) [org/10.1186/s13567-024-01347-1](https://doi.org/10.1186/s13567-024-01347-1).

Additional fle 1. Marine and freshwater (including ornamental) fsh susceptible to *Iridoviridae* **infections.**

Acknowledgements

In memoriam: This article is dedicated to Dr M. C. Sarasquete, a great scientist and better friend.

Authors' contributions

All the authors have contributed signifcantly to the manuscript. JJB, RLR, and AML wrote the manuscript and designed the study. JJB, DC, and JGM reviewed the information about marine and freshwater fsh susceptible to *Iridoviridae* infections. AML and RLR designed and collected information of diferent vaccines in the subfamily *Alphairidovirinae*. DC and JGM revised the manuscript. All authors read and approved the fnal manuscript.

Funding

This research was funded by the Junta de Andalucia under Grant PCM_00059 (Proyectos de I+D+i en el marco del Plan Complementario de Ciencias Marinas).

Data availability

Not applicable.

Declarations

Competing interests

The authors declare that they have no competing interests.

Received: 4 December 2023 Accepted: 31 May 2024 Published online: 15 July 2024

References

- 1. Valero Y, Cuesta A (2023) Reassortant viruses threatening fish aquaculture. Rev Aquacult 15:1720–1731
- 2. Mugimba KK, Byarugaba DK, Mutoloki S, Evensen Ø, Munang'andu HM (2021) Challenges and solutions to viral disease of fnfsh in marine aquaculture. Pathogens 9:673
- 3. Du Y, Hu X, Miao L, Chen J (2022) Current status and development prospects of aquatic vaccines. Front Immunol 13:1040336
- 4. Długosz E, Wesołowska A (2023) Immune response of the host and vaccine development. Pathogens 12:637
- 5. Sakai M (1999) Current research status of fish immunostimulants. Aquaculture 172:63–92
- 6. Ma J, Bruce TJ, Jones EM, Cain KD (2019) A review of fish vaccine development strategies: conventional methods and modern biotechnological approaches. Microorganisms 7:569
- 7. Aida V, Pliasas VC, Neasham PJ, North JF, McWhorter KL, Glover SR, Kyriakis CS (2021) Novel vaccine technologies in veterinary medicine: a herald to human medicine vaccines. Front Vet Sci 8:654289
- 8. Dong F, Tacchi L, Xu Z, Scott E, Salinas I (2020) Vaccination route determines the kinetics and magnitude of nasal innate immune responses in rainbow trout (*Oncorhynchus mykiss*). Biology 9:319
- 9. Monda H, Thomas J (2022) A review on the recent advances and application of vaccines against fsh pathogens in aquaculture. Aquac Int 30:1971–2000
- 10. Angulo C, Tello-Olea M, Reyes-Becerril M, Monreal-Escalante E, Hernández-Adame L, Angulo M, Mazon-Suastegui JM (2021) Developing oral nanovaccines for fsh: a modern trend to fght infectious diseases. Rev Aquac 13:1172–1192
- 11. Plant KP, LaPatra SE (2011) Advances in fsh vaccine delivery. Dev Com Immunol 35:1256–1262
- 12. Jaafar RM, Al-Jubury A, Dalsgaard I, Mohammadkarami A, Kania PW, Buchmann K (2019) Efect of oral booster vaccination of rainbow trout against *Yersinia ruckeri* depends on type of primary immunization. Fish Shellfsh Immunol 85:61–65
- 13. Bøgwald J, Dalmo RA (2019) Review on immersion vaccines for fsh: an update 2019. Microorganisms 7:627
- 14. Mondal H, Thomas J (2022) A review on the recent advances and application of vaccines against fsh pathogens in aquaculture. Aquac Int 30:1971–2000
- 15. Jose Priya TA, Kappalli S (2022) Modern biotechnological strategies for vaccine development in aquaculture—prospects and challenges. Vaccine 40:5873–5881
- 16. Klafack S, Schroder L, Jin Y, Lenk M, Lee PY, Fluchs W, Avarre JC, Bergmann SM (2022) Development of an attenuated vaccine against Koi Herpesvirus Disease (KHVD) suitable for oral administration and immersion. NPJ Vaccines 7:106
- 17. Cárdenas C, Guzmán F, Carmona M, Muñoz C, Nilo L, Labra A, Marshall SH (2020) Synthetic peptides as a promising alternative to control viral infections in Atlantic salmon. Pathogens 9:600
- 18. Wang Q, Ji W, Xu Z (2020) Current use and development of fish vaccines in China. Fish Shellfsh Immunol 96:223–234
- 19. Dalmo RA (2018) DNA vaccines for fsh: review and perspectives on correlates of protection. J Fish Dis 41:1–9
- 20. Røsaeg MV, Thorarinsson R, Aunsmo A (2021) Efect of vaccines against pancreas disease in farmed Atlantic salmon. J Fish Dis 44:1911–1924
- 21. Xu L, Zhao J, Liu M, Ren G, Jian F, Yin J, Feng J, Liu H, Lu T (2017) Bivalent DNA vaccine induces signifcant immune responses against infectious hematopoietic necrosis virus and infectious pancreatic necrosis virus in rainbow trout. Sci Rep 7:5700
- 22. Aonullah AA, Nuryati S, Alimuddin MS (2017) Efficacy of koi herpesvirus DNA vaccine administration by immersion method on *Cyprinus carpio* feld scale culture. Aquac Res 48:2655–2662
- 23. Pardi N, Hogan MJ, Porter FW, Weissman D (2018) mRNA vaccines—a new era in vaccinology. Nat Rev Drug Discov 17:261–279
- 24. Gote V, Bolla PK, Kmmineni N, Butreddy A, Nukala PK, Palakurthi SS, Khan W (2023) A comprehensive review of mRNA vaccines. Int J Mol Sci 24:2700
- 25. Muñoz-Atienza E, Diaz-Rosales P, Tafalla C (2021) Systemic and mucosal B and T cell responses upon mucosal vaccination of teleost fsh. Front Immunol 11:622377
- 26. Gheibi Hayat SM, Darroudi M (2019) Nanovaccine: a novel approach in immunization. J Cell Physiol 234:12530–12536
- 27. Chinchar VG, Hick P, Ince IA, Jancovich JK, Marschang R, Qin Q, Subramaniam K, Waltzek TB, Whittington R, Williams T, Zhang QY, ICTV Report Consortium (2017) ICTV virus taxonomy profle: *Iridoviridae*. J Gen Virol 98:890–891
- 28. Subramaniam K, Shariff M, Omar AR, Hair-Bejo M (2012) Megalocytivirus infection in fsh. Rev Aquac 4:221–233
- 29. Maclachlan NJ, Dubovi EJ (2017) Asfarviridae and Iridoviridae. Fenner's vete virol, 5th edn. Academic Press, USA, pp 175–188
- 30. Fu Y, Li Y, Fu W, Su H, Zhang L, Huang C, Weng S, Yu F, He J, Dong C (2021) Scale drop disease virus associated yellowfn seabream (*Acanthopagrus latus*) ascites diseases, Zhuhai, Guangdong, Southern China: the frst description. Viruses 13:1617
- 31. Fu W, Li Y, Fu Y, Zhang W, Luo P, Sun Q, Yu F, Weng S, Li W, He J, Dong C (2023) The inactivated ISKNV-I vaccine confers highly effective crossprotection against epidemic RSIV-I and RSIV-II from cultured spotted sea bass *Lateolabrax maculatus*. Microbiol Spectr 11:e04495-22
- 32. Koda SA, Subramaniam K, Hick PM, Hall K, Waltzek TB, Becker JA (2023) Partial validation of a TaqMan quantitative polymerase chain reaction for the detection of the three genotypes of Infectious spleen and kidney necrosis virus. PLoS One 18:e0281292
- 33. Azarulzaman C, Johan C, Zainathan SC (2020) Megalocytiviruses in ornamental fsh: a review. Vet World 13:2565–2577
- 34. Kerddee P, Dong HT, Chokmangmeepisarn P, Rodkhum C, Srisapoome P, Areechon N, Del-Pozo J, Kayansamruaj P (2020) Simultaneous detection of scale drop disease virus and *Flavobacterium columnare* from diseased freshwater-reared barramundi *Lates calcarifer*. Dis Aquat Org 140:119–128
- 35. Thanasaksiri K, Takano R, Fukuda K, Chaweepack T, Wongtavatchai J (2019) Identifcation of infectious spleen and kidney necrosis virus from farmed barramundi *Lates calcarifer* in Thailand and study of its pathogenicity. Aquaculture 5000:188–191
- 36. Kurita J, Nakajima K (2012) Megalocytiviruses. Viruses 4:521–538
- 37. Yanong RPE, Waltzek TB (2019) *Megalocytivirus* infections in fsh*,* with emphasis on ornamental species, Circular FA-182. University of Florida, Gainesville
- 38. World Organisation for Animal Health (WOAH) (2023). Infection with red sea bream iridovirus. Chapter 10.8. [https://www.woah.org/flea](https://www.woah.org/fileadmin/Home/eng/Health_standards/aahc/current/chapitre_rsbid.pdf) [dmin/Home/eng/Health_standards/aahc/current/chapitre_rsbid.pdf.](https://www.woah.org/fileadmin/Home/eng/Health_standards/aahc/current/chapitre_rsbid.pdf)
- Anders K (1989) Lymphocystis disease of fishes. In: Ahne W, Kurstak D (eds) Viruses of lower vertebrates. Springer, Berlin, pp 141–160
- 40. Alonso MC, Ferro P, Garcia-Rosado E, Cano I, Lang T, Bergmann S, Borrego JJ (2007) Comparison of lymphocystis disease virus (LCDV) isolates obtained from diferent marine fsh species and geographical areas. Bull Eur Assoc Fish Pathol 27:155–162
- 41. Perretta A, Doszpoly A, Puentes R, Bessonart M (2020) Diagnosis of lymphocystis disease in a novel host, the white mouth croaker *Micropogonias furnieri*, associated with a putatively novel *Lymphocystivirus* species (LCDV-WC). Dis Aquat Org 137:185–193
- 42. Williams T, Barbosa-Solomieu V, Chinchar VG (2005) A decade of advances in iridovirus research. Adv Virus Res 65:173–248
- 43. Rahmati-Holasoo H, Ghalyanchilangeroudi A, Kaf ZZ, Marandi A, Shokrpoor S, Imantalab B, Mousavi EH (2023) Detection of lymphocystis disease virus (LCDV) from yellowbar angelfsh (*Pomacanthus maculosus* Forsskål, 1775) in Iran: histopathological and phylogenetic analysis. Aquaculture 562:738862
- 44. Wirth W, Schwarzkopf L, Skerratt LF, Ariel E (2018) Ranaviruses and reptiles. Peer J 6:e6083
- Brenes R, Gray MJ, Waltzek TB, Wilkes RP, Miller DL (2014) Transmission of *Ranavirus* between ectothermic vertebrate hosts. PLoS One 9:e92476
- 46. Herath J, Sun D, Ellepola G, Subramaniam K, Meegaskumbura M (2023) Emerging threat of ranavirus: prevalence, genetic diversity, and climatic drivers of Ranavirus (*Iridoviridae*) in ectothermic vertebrates of Asia. Front Vet Sci 10:1291872
- 47. World Organisation for Animal Health (WOAH). 2021. [https://www.](https://www.woah.org/app/uploads/2021/03/ranavirusesinfection-with.pdf) [woah.org/app/uploads/2021/03/ranavirusesinfection-with.pdf](https://www.woah.org/app/uploads/2021/03/ranavirusesinfection-with.pdf).
- 48. Chinchar VG, Waltzek TB (2014) Ranaviruses: not just for frogs. PLoS Pathog 10:e1003850
- 49. Duffus ALJ, Waltzek TB, Stohr AC, Allender MC, Gotesman M, Whittington RJ, Hick P, Hines MK, Marschang RE (2015) Distribution and host range of ranaviruses. In: Gray MJ, Chinchar VG (eds) *Ranavirus:* lethal pathogens of ectothermic vertebrates. Springer, New York, pp 9–57
- 50. Whittington RJ, Becker JA, Dennis MM (2010) Iridovirus infections in fnfsh—a critical review with emphasis on ranaviruses. J Fish Dis 33:95–122
- 51. Ulmer JB, Mason PW, Geall A, Mandl CW (2012) RNA-based vaccines. Vaccine 30:4414–4418
- 52. Siwicki AK, Pozet F, Morand M, Volatier C, Terah-Majewska E (1999) Effects of iridovirus-like agent on the cell-mediated immunity in sheatfsh (*Silurusglanis*)—an in vitro study. Virus Res 63:115–119
- 53. Caipang CMA, Hirono I, Aoki T (2003) *In vitro* inhibition of fsh rhab‑ doviruses by Japanese founder, *Paralichthys olivaceus* Mx. Virology 317:373–382
- 54. Wu YC, Chi SC (2007) Cloning and analysis of antiviral activity of a barramundi (*Lates calcarifer*) Mx gene. Fish Shellfsh Immunol 23:97–108
- 55. Alvarez-Torres D, Garcia-Rosado E, Fernandez-Trujillo MA, Bejar J, Alvarez MC, Borrego JJ, Alonso MC (2013) Antiviral specifcity of the *Solea senegalensis* Mx protein constitutively expressed in CHSE-214 cells. Mar Biotechnol 15:125–132
- 56. Lester K, Hall M, Urquhart K, Gahlawat S, Collet B (2012) Development of an in vitro system to measure the sensitivity to the antiviral Mx protein of fsh viruses. J Virol Methods 182:1–8
- 57. Fernández-Trujillo MA, Garcia-Rosado E, Alonso MC, Castro D, Alvarez MC, Bejar J (2013) Mx1, Mx2, and Mx3 proteins from the gilthead seabream (*Sparus aurata*) show *in vitro* antiviral activity against RNA and DNA viruses. Mol Immunol 56:630–636
- 58. Chao C-B, Chen C-Y, Lai Y-Y, Lin C-S, Huang H-T (2004) Histological, ultrastructural, and *in situ* hybridization study on enlarged cells in grouper *Epinephelus* hybrids infected by grouper iridovirus in Taiwan (TGIV). Dis Aquat Org 58:127–142
- 59. Banjara S, Mao J, Ryan TM, Caria S, Kvansakul M (2018) Grouper iridovirus GIV66 is a Bcl-2 protein that inhibits apoptosis by exclusively sequestering Bim. J Biol Chem 293:5464–5477
- 60. Yu Y, Huang Y, Wei S, Li P, Zhou L, Ni S, Huang X, Qin Q (2016) A tumour necrosis factor receptor-like protein encoded by Singapore grouper iridovirus modulates cell proliferation, apoptosis and viral replication. J Gen Virol 97:756–766
- 61. Li C, Wang L, Liu J, Yu Y, Huang Y, Huang X, Wei J, Qin Q (2020) Singapore grouper iridovirus (sgiv) inhibited autophagy for efficient viral replication. Front Microbiol 11:1446
- 62. Holopainen R, Tapiovaara H, Honkanen J (2012) Expression analysis of immune response genes in fsh epithelial cells following ranavirus infection. Fish Shellfsh Immunol 32:1095–1105
- 63. Das K, Rao LVM (2022) The role of microRNAs in infammation. Int J Mol Sci 23:15479
- 64. Andreassen R, Høyheim B (2017) miRNAs associated with immune response in teleost fsh. Dev Comp Immunol 75:77–85
- 65. Li PH, Wang LQ, He JY, Zhu XL, Huang W, Wang SW, Qin QW, Sun HY (2021) MicroRNA-124 promotes Singapore grouper iridovirus replica‑ tion and negatively regulates innate immune response. Front Immunol 12:767813
- 66. Wu Q, Ning X, Sun L (2021) Megalocytivirus induces complicated fsh immune response at multiple RNA levels involving mRNA, miRNA, and circRNA. Int J Mol Sci 22:3156
- 67. Huang Y, Huang X, Yan Y, Cai J, Ouyang Z, Cui H, Wang P, Qin Q (2011) Transcriptome analysis of orange-spotted grouper (*Epinephelus coioides*) spleen in response to Singapore grouper iridovirus. BMC Genomics 12:556
- 68. Park J-H, Jeong HD, Hong S (2016) Analysis of immune gene expression in rock bream spleen after rock bream iridovirus infection by transcriptome sequencing. Fish Shellfsh Immunol 53:123
- 69. Carballo C, Castro D, Borrego JJ, Manchado M (2017) Gene expression profiles associated with lymphocystis disease virus (LCDV) in experimentally infected Senegalese sole (*Solea senegalensis*). Fish Shellfsh Immunol 66:129–139
- 70. Hu GB, Lou HM, Dong XZ, Liu QM, Zhang SC (2012) Characteristics of the interferon regulatory factor 5 (IRF5) and its expression in response to LCDV and poly I: C challenges in Japanese founder, *Paralichthys olivaceu*s. Dev Comp Immunol 38:377–382
- 71. Liu CC, Ho LP, Yang CH, Kao TY, Chou HY, Pai TW (2017) Comparison of grouper infection with two diferent iridoviruses using transcriptome sequencing and multiple reference species selection. Fish Shellfsh Immunol 71:264–274
- 72. Leiva-Rebollo R, Labella AM, Borrego JJ, Castro D (2019) Immune gene expression in gilthead seabream (*Sparus aurata*) after lymphocystis disease virus (LCDV-Sa) challenge resulting in asymptomatic infection. J Appl Microbiol 128:41–53
- 73. Carballo C, Ortiz-Delgado JB, Berbel C, Castro D, Borrego JJ, Sarasquete C, Manchado M (2019) Feed and immersion challenges with lymphocystis disease virus (LCDV) reveals specifc mechanisms for horizontal transmission and immune response in Senegalese sole post-larvae. Fish Shellfsh Immunol 89:710–718
- 74. Yang M, Wang Q, Wang S, Wang Y, Zeng Q, Qin Q (2019) Transcriptomics analysis reveals candidate genes and pathways for susceptibility or resistance to Singapore grouper iridovirus in orange-spotted grouper (*Epinephelus coioides*). Dev Comp Immunol 90:70–79
- 75. Yu Y, Li C, Wang Y, Wang Q, Wang S, Wei S, Yang M, Qin Q (2019) Molecular cloning and characterization of grouper Krϋppel-like factor 9 gene: involvement in the fsh immune response to viral infection. Fish Shellfsh Immunol 89:677–686
- 76. Cai YJ, Li PH, Wang XA, Xu YM, Yang S, Tang YN, Zhu Z, Yang XY, He JY, Luo H, Zhang T, Qi H, Chen X, Qin QW, Sun HY (2022) *Epinephelus coioides* PCSK9 afect the infection of SGIV by regulating the innate immune response. Fish Shellfsh Immunol 126:113–121
- 77. Kim A, Yoon D, Lim Y, Roh HJ, Kim S, Park CI, Kin HS, Cha HJ, Choi YH, Kim DH (2020) Co-expression network analysis of spleen transcriptome in rock bream (*Oplegnathus fasciatus*) naturally infected with rock bream iridovirus (RBIV). Int J Mol Sci 21:1707
- 78. Domingos JA, Shen X, Terence C, Senapin S, Dong HT, Tan MR, Gibson-Kueh S, Jerry DR (2021) Scale drop disease virus (SDDV) and *Lates calcarifer* herpes virus (LCHV) coinfection downregulate immune-relevant pathways and cause splenic and kidney necrosis in barramundi under commercial farming conditions. Front Genetics 12:666897
- 79. Zheng G, Zhou Q, Li K, Xu W, Wang L, Hu G, Chen SL (2020) Transcriptome analysis of giant grouper (*Epinephelus lanceolatus*) kidney and spleen in response to spotted knifejaw iridovirus (SKIV) infection. Aquac Res 52:1954–1964
- 80. Niu Y, Fu X, Lin Q, Liang H, Luo X, Zuo S, Liu L, Li N (2022) The composition and antiviral activity of scTRIM59 in Mandarin fsh. Fish Shellfsh Immunol 130:86–92
- 81. Liang M, Pan W, You Y, Qin X, Su H, Zhan Z, Guo SPWC, He J (2024) Hypermethylated genome of a fsh vertebrate iridovirus ISKNV plays important roles in viral infection. Commun Biol 7:237
- 82. Guo X, Wang W, Zheng Q, Qin Q, Huang Y, Huang X (2022) Comparative transcriptomic analysis reveals different host cell responses to Singapore grouper iridovirus and red-spotted grouper nervous necrosis virus. Fish Shellfsh Immunol 128:136–147
- Dhar AK, Manna SK, Allnutt FCT (2014) Viral vaccines for farmed finfish. Virusdisease 25:1–17
- 84. Yuting W, Yong L, Wenfeng Z, Weixuan F, Wangdong L, Zhiming Z, Shaoping W, Jianguo H, Chuanfu D (2023) Efectively protecting Asian seabass *Lates calcarifer* from ISKNV-I, ISKNV-II, RSIV-II and SDDV by an inactivated ISKNV-I and SDDV bivalent vaccine. Aquaculture 566:739218
- 85. Nakajima K, Maeno Y, Kurita J, Inui Y (1997) Vaccination against red sea bream iridoviral disease in red sea bream. Fish Pathol 32:205–209
- 86. Nakajima K, Maeno Y, Honda A, Yokoyama K, Tooriyama K, Manabe S (1999) Efectiveness of a vaccine against red sea bream iridoviral disease in a feld trial test. Dis Aquat Organ 36:73–75
- 87. Caipang CMA, Hirono I, Aoki T (2006) Immunogenicity, retention and protective efects of the protein derivatives of formalin-inactivated red seabream iridovirus (RSIV) vaccine in red seabream, *Pagrus major*. Fish Shellfsh Immunol 20:597–609
- 88. Kwon WJ, Choi JC, Hong S, Kim YC, Jeong MG, Min JG, Min JG, Jeong JB, Kim KI, Jeong HD (2020) Development of a high-dose vaccine formulation for prevention of megalocytivirus infection in rock bream (*Oplegnathus fasciatus*). Vaccine 38:8107–8115
- 89. Shimmoto H, Kawai K, Ikawa T, Oshima S (2010) Protection of red sea bream *Pagrus major* against red sea bream iridovirus infection by vaccination with a recombinant viral protein. Microbiol Immunol 54:135–142
- 90. Park SJ, Seo HJ, Son JH, Kim HJ, Kim YI, Nam YK, Kim SK (2005) Development of DNA vaccine against red sea bream iridovirus (RSIV). J Microbiol Biotechnol 15:873–879
- 91. Caipang CMA, Takano T, Hirono I, Aoki T (2006) Genetic vaccines protect red seabream, *Pagrus major*, upon challenge with red seabream iridovirus (RSIV). Fish Shellfsh Immunol 21:130–138
- 92. Fan T, Hu X, Wang L, Geng X, Jiang G, Yang X, Yu M (2012) Development of an inactivated iridovirus vaccine against turbot viral reddish body syndrome. J Ocean Univ China 11:65–69
- 93. Zheng F, Liu H, Sun X, Qin X, Xu Z, Wang B (2017) Construction and expression of DNA vaccine against reddish body iridovirus and evaluation of immune efficacy in turbot (*Scophthalmus maximus*). Aquac Res 48:4174–4183
- 94. Dong C, Xiong X, Luo Y, Weng S, Wang Q, He J (2013) Efficacy of a formalin-killed cell vaccine against infectious spleen and kidney necrosis virus (ISKNV) and immunoproteomic analysis of its major immunogenic proteins. Vet Microbiol 162:419–428
- 95. Zeng R, Pan W, Lin Y, He J, Luo Z, Li Z, Weng S, He J, Guo C (2021) Development of a gene-deleted live attenuated candidate vaccine against fsh virus (ISKNV) with low pathogenicity and high protection. iScience 24:102750
- 96. Fu X, Li N, Lai Y, Liu L, Lin Q, Shi C, Huang Z, Wu S (2012) Protective immunity against iridovirus disease in mandarin fsh, induced by recombinant major capsid protein of infectious spleen and kidney necrosis virus. Fish Shellfsh Immunol 33:880–885
- 97. Fu X, Li N, Lin Q, Guo H, Zhang D, Liu L, Wu S (2014) Protective immunity against infectious spleen and kidney necrosis virus induced by immunization with DNA plasmid containing *mcp* gene in Chinese perch *Siniperca chuatsi*. Fish Shellfsh Immunol 40:259–266
- 98. Li N, Fu X, Guo H, Lin Q, Liu L, Zhang D, Fang X, Wu S (2015) Protein encoded by ORF093 is an efective vaccine candidate for infectious spleen and kidney necrosis virus in Chinese perch *Siniperca chuatsi*. Fish Shellfsh Immunol 42:88–90
- 99. Fu X, Li N, Lin Q, Guo H, Liu L, Huang Z, Wu S (2015) Early protein ORF086 is an efective vaccine candidate for infectious spleen and kidney necrosis virus in mandarin fsh *Siniperca chuatsi*. Fish Shellfsh Immunol 46:200–205
- 100. Throngnumchai B, Jitrakor S, Sangsuriya P, Unajak S, Khunrae P, Dong HT, Saksmerprome V, Rattanarojpong T (2021) Refolded recombinant major capsid protein (MCP) from infectious spleen and kidney necrosis virus (ISKNV) efectively stimulates serum specifc antibody and immune related genes response in Nile tilapia (*Oreochromis niloticus*). Protein Expr Purif 184:105876
- 101. Zhao Z, Zhang C, Lin Q, Lia N-Q, Huang Z-B, Zhao M, Fu X-Z, Wang G-X, Zhu B (2020) Single-walled carbon nanotubes as delivery vehicles enhance the immunoprotective efect of an immersion DNA vaccine against infectious spleen and kidney necrosis virus in mandarin fsh. Fish Shellfsh Immunol 97:432–439
- 102. Zhao Z, Zhang C, Jia Y-J, Qiu D-K, Lin Q, Li N-Q, Huang Z-B, Fu X-Z, Wang G-X, Zhu B (2019) Immersion vaccination of Mandarin fsh *Siniperca chuatsi* against infectious spleen and kidney necrosis virus with a SWCNTs-based subunit vaccine. Fish Shellfsh Immunol 92:133–140
- 103. Liu GY, Wang EL, Qu XY, Yang KC, Zhang ZY, Liu JY, Zhang C, Zhu B, Wang GX (2020) Single-walled carbon nanotubes enhance the immune protective efect of a bath subunit vaccine for pearl gentian grouper against Iridovirus of Taiwan. Fish Shellfsh Immunol 106:510–517
- 104. Zhu M, Shen Z, Gu Y, Tong X, Zhang Y, Pan J, Feng Y, Hu X, Wang Y, Cao G, Xue R, Gong C (2023) A recombinant baculovirus vector vaccine (BacMCP) against the infectious spleen and kidney necrosis virus (ISKNV). J Fish Dis 46:165–176
- 105. Shin YS, Kwon TH, Seo JY, Kim TJ (2013) Oral immunization of fsh against iridovirus infection using recombinant antigen produced from rice callus. Vaccine 31:5210–5215
- 106. Jung MH, Kole S, Jung SJ (2022) Efficacy of saponin-based inactivated rock bream iridovirus (RBIV) vaccine in rock bream (*Oplegnathus fasciatus*). Fish Shellfsh Immunol 121:12–22
- 107. Ahn G, Cha JY, Lee JW, Park G, Shin GI, Song SJ, Ryu G, Hwang I, Kim MG, Kim WY (2022) Production of a bacteria-like particle vaccine targeting rock bream (*Oplegnathus fasciatus*) iridovirus using *Nicotiana benthamiana*. J Plant Biol 65:21–28
- 108. Jung MH, Nikapitiya C, Jung SJ (2018) DNA vaccine encoding myristoylated membrane protein (MMP) of rock bream iridovirus (RBIV) induces protective immunity in rock bream (*Oplegnathus fasciatus*). Vaccine 36:802–810
- 109. Jung MH, Nikapitiya C, Kim SJ, Han HJ, Kim M-S, Choi HS, Jung SJ (2022) Protective immunity induced by ankyrin repeat-containing

protein-based DNA vaccine against rock bream iridovirus (RBIV) in rock bream (*Oplegnathus fasciatus*). Virus Res 318:198827

- 110. Mahardika K, Mastuti I (2015) The efects of crude recombinant viral protein vaccines against grouper sleepy disease iridovirus (GSDIV) on humpback grouper (*Cromileptes altivelis*). Indones Aquac J 10:163–172
- 111. Guo X, Zhou Y, Fu X, Lin Q, Liu L, Liang H, Niu Y, Li N (2020) Transcriptomic profiles reveal that inactivated iridovirus and rhabdovirus bivalent vaccine elicits robust adaptive immune responses against lethal challenge in marbled sleepy goby. Fish Shellfsh Immunol 98:429–437
- 112. Zheng FR, Sun WQ, Liu HZ, Zhang JX (2006) Study on the distribution and expression of a DNA vaccine against lymphocystis disease virus in Japanese founder (*Paralichthys olivaceus*). Aquaculture 261:1128–1134
- 113. Tian J, Sun X, Chen X, Yu J, Qu L, Wang L (2008) The formulation and immunization of oral poly (DL-lactide-co-glycolide) microcapsules containing a plasmid vaccine against lymphocystis disease virus in Japanese founder (*Paralichthys olivaceus*). Int Immunopharmacol 8:900–908
- 114. Tian J, Yu J (2011) Poly (lactic-co-glycolic acid) nanoparticles as candidate DNA vaccine carrier for oral immunization of Japanese founder (*Paralichthys olivaceus*) against lymphocystis disease virus. Fish Shellfsh Immunol 30:109–117
- 115. Zheng FR, Sun XQ, Xing MQ (2010) Immune response of DNA vaccine against lymphocystis disease virus and expression analysis of immunerelated genes after vaccination. Aquac Res 41:1444–1451
- 116. Zheng F, Sun X, Wu X, Liu H, Li J, Wu S, Zhang J (2011) Immune efficacy of a genetically engineered vaccine against lymphocystis disease virus: analysis of diferent immunization strategies. Evid Based Complement Alternat Med 2011:729216
- 117. Leiva-Rebollo R, Castro D, Moreno P, Borrego JJ, Labella AM (2021) Evaluation of gilthead seabream (*Sparus aurata*) immune response after LCDV-Sa DNA vaccination. Animals 11:1613
- 118. Leiva-Rebollo R, Gemez-Mata J, Castro D, Borrego JJ, Labella AM (2023) Immune response of DNA vaccinated-gilthead seabream (*Sparus aurata*) against LCDV-Sa infection: relevance of the inflammatory process. Front Immunol 14:1209926
- 119. Ou-yang Z, Wang P, Huang X, Cai J, Huang Y, Wei S, Ji H, Wei J, Zhou Y, Qin Q (2012) Immunogenicity and protective effects of inactivated Singapore grouper iridovirus (SGIV) vaccines in orange-spotted grouper, *Epinephelus coioides*. Dev Comp Immunol 38:254–261
- 120. Ma H, Cheng C, Deng Y, Liu G, Fan S, Feng J, Guo Z (2022) Efective protection against ranavirus-type grouper iridovirus and *Vibrio harveyi* by priming a bivalent grouperVAC-Irido-R-Vh followed by boosting a monovalent *V. harveyi* vaccine. Aquaculture 560:738455
- 121. Yu NT, Zheng XB, Liu ZX (2019) Protective immunity induced by DNA vaccine encoding viral membrane protein against SGIV infection in grouper. Fish Shellfsh Immunol 92:649–654
- 122. Liang X, Liang J, Cao J, Liu S, Wang Q, Ning Y, Liang Z, Zheng J, Zhang Z, Luo J, Chen Y, Huang X, Huang Y, Qin Q, Zhou S (2023) Oral immunizations with *Bacillus subtilis* spores displaying VP19 protein provide pro‑ tection against *Singapore grouper iridovirus* (SGIV) infection in grouper. Fish Shellfsh Immunol 138:108860
- 123. Yi W, Zhang X, Zeng K, Xie DF, Song C, Tam K, Liu Z, Zhou T, Li W (2020) Construction of a DNA vaccine and its protective effect on largemouth bass (*Micropterus salmoides*) challenged with largemouth bass virus (LMBV). Fish Shellfsh Immunol 106:103–109
- 124. Hossain M, Kim SR, Kitamura SI, Kim DW, Jung SJ, Nishizawa T, Yoshimiza M, Oh MJ (2009) Lymphocystis disease virus persists in the epidermal tissues of olive founder, *Paralichthys olivaceus* (Temminch & Schlegel), at low temperatures. J Fish Dis 32:699–703
- 125. Iwakiri S, Song J, Nakayama K, Oh M, Ishida M, Kitamura S (2014) Host responses of Japanese flounder *Paralichthys olivaceus* with lymphocystis cell formation. Fish Shellfsh Immunol 38:406–411
- 126. Rayl JM, Allender MC (2020) Temperature affects the host hematological and cytokine response following experimental ranavirus infection in red-eared sliders (*Trachemys scripta elegans*). PLoS One 15:e0241414
- 127. Infection with ranavirus. Chapter 2.1.2 WOAH. 2019. [https://www.woah.](https://www.woah.org/fileadmin/Home/eng/Health_standards/aahm/current/chapitre_ranavirus.pdf) [org/fleadmin/Home/eng/Health_standards/aahm/current/chapitre_](https://www.woah.org/fileadmin/Home/eng/Health_standards/aahm/current/chapitre_ranavirus.pdf) [ranavirus.pdf](https://www.woah.org/fileadmin/Home/eng/Health_standards/aahm/current/chapitre_ranavirus.pdf).
- 128. Zhang W, Duan C, Zhang H, Weng S, He J, Dong C (2020) Widespread outbreaks of the emerging mandarinfsh ranavirus (MRV) both in

natural and ISKNV -FKC vaccinated mandarin fsh *Siniperca chuatsi* in Guangdong, South China, 2017. Aquaculture 520:734989

- 129. Huang Z, Tang J, Li M, Fu Y, Dong C, Zhong JF, He J (2012) Immunological evaluation of *Vibrio alginolyticus*, *Vibrio harveyi*, *Vibrio vulnifcus* and infectious spleen and kidney necrosis virus (ISKNV) combined -vaccine efficacy in *Epinephelus coioides*. Vet Immunol Immunopathol 150:61-68
- 130. Reddacliff LA, Whittington RJ (1996) Pathology of epizootic haematopoietic necrosis virus (EHNV) infection in rainbow trout (*Oncorhynchus mykiss* Walbaum) and redfn perch (*Perca fuviatilis* L). J Comp Pathol 115:103–115
- 131. Fu X, Lin Q, Liu L, Liang H, Huang Z, Li N (2016) Display of ISKNV orf086 protein on the surface of *Aeromonas hydrophila* and its immunogenicity in Chinese perch (*Siniperca chuatsi*). Fish Shellfsh Immunol 56:286–293
- 132. Oh S -Y, Oh M -J, Nishizawa T (2014) Potential for a live red seabream iridovirus (RSIV) vaccine in rock bream *Oplegnathus fasciatus* at a low rearing temperature. Vaccine 32:363–368
- 133. Rondón -Barragán I, Nozak R, Hirono I, Kondo H (2017) LAMP -1 -chimeric DNA vaccines enhance the antibody response in Japanese founder, *Paralichthys olivaceus*. Fish Shellfsh Immunol 67:546–553
- 134. Tamaru Y, Ohtsuka M, Kato K, Manabe S, Kuroda K, Sanada M, Ueda M (2006) Application of the arming system for the expression of the 380R antigen from red sea bream iridovirus (RSIV) on the surface of yeast cells: a frst step for the development of an oral vaccine. Biotechnol Prog 22:949–953
- 135. Zhang Z, Liu G, Liu J, Zhu B, Wang G, Ling F (2021) Epitope screening of the major capsid protein within grouper iridovirus of Taiwan and the immunoprotective effect with SWCNTs as the vaccine carrier. Fish Shellfsh Immunol 117:17–23
- 136. Zhang J, Li M -F (2015) ORF75 of megalocytivirus RBIV -C1: a global transcription regulator and an efective vaccine candidate. Fish Shellfsh Immunol 45:486–494
- 137. Zhang M, Hu YH, Xiao ZZ, Sun Y, Sun L (2012) Construction and analysis of experimental DNA vaccines against megalocytivirus. Fish Shellfsh Immunol 33:1192–1198
- 138. Seo JY, Chung HJ, Kim TJ (2013) Codon -optimized expression of fsh iridovirus capsid protein in yeast and its application as an oral vaccine candidate. J Fish Dis 36:763–768
- 139. de Groof A, Guelen L, Deijs M, van der Wal Y, Miyata M, Ng K, van Grins ‑ ven L, Simmelink B, Biermann Y, Grisez L, van Lent J, de Ronde A, Chang SF, Schrier C, van der Hoek L (2015) A novel virus causes scale drop disease in *Lates calcarifer*. PLoS Pathog 11:e1005074
- 140. Chansuwan S, Akeprathumchai S, Poomputsa K (2021) Production of scale drop disease virus self-assembled major capsid protein nanoparti ‑ cles for fsh vaccine development. Thai J Sci Technol 9:729–740
- 141. Jang HB, Kim YR, Cha IS, Noh SW, Park SB, Ohtani M, Hikima J, Aoki T, Jung TS (2011) Detection and antigenic proteins expressed by lympho ‑ cystis virus as vaccine candidates in olive founder, *Paralichthys olivaceus* (Temminck & Schlegel). J Fish Dis 34:555–562
- 142. Jia YJ, Guo ZR, Ma R, Qiu DK, Zhao Z, Wang GX, Zhu B (2020) Immune efficacy of carbon nanotubes recombinant subunit vaccine against largemouth bass ulcerative syndrome virus. Fish Shellfsh Immunol 100:317–323
- 143. Yao JY, Zhang CS, Yuan XM, Huang L, Hu DY, Yu Z, Yin WL, Lin LY, Pan XY, Yang GL, Wang CF, Shen JY, Zhang HQ (2022) Oral vaccination with recombinant *Pichia pastoris* expressing iridovirus major capsid protein elicits protective immunity in largemouth bass (*Micropterus salmoides*). Front Immunol 13:852300
- 144. Zhang M, Chen X, Xue M, Jiang N, Li Y, Fan Y, Zhang P, Liu N, Xiao Z, Zhang Q, Zhou Y (2023) Oral vaccination of largemouth bass (*Microp terus salmoides*) against largemouth bass ranavirus (LMBV) using yeast surface display technology. Animals (Basel) 13:1183
- 145. Wang Q, Liang X, Ning Y, Liu S, Liang Z, Zhang Z, Chen Y, Cao J, Wang F, Lan L, Cheng G, Huang Y, Huang Y, Qin Q, Zhou S (2023) Surface display of major capsid protein on *Bacillus subtilis* spores against largemouth bass virus (LMBV) for oral administration. Fish Shellfsh Immunol 135:108627

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in pub ‑ lished maps and institutional afliations.